NASDAQ: ALMSAlumis Inc Stock
$4.33+0.21 (+5.1%)
Updated Apr 29, 2025
ALMS Price
$4.33
Fair Value Price
$4.90
Market Cap
$235.58M
52 Week Low
$3.18
52 Week High
$13.53
P/E
-0.42x
P/B
0.91x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$294.23M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.31
Operating Cash Flow
-$255M
Beta
0.44
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ALMS Overview
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ALMS's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ALMS
Ranked#422 of 462
Ranked#422 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.96 | A | |
| $8.12 | A | |
| $24.28 | A |
Be the first to know about important ALMS news, forecast changes, insider trades & much more!
ALMS News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ALMS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ALMS ($4.33) is undervalued by 11.59% relative to our estimate of its Fair Value price of $4.90 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ALMS ($4.33) is not significantly undervalued (11.59%) relative to our estimate of its Fair Value price of $4.90 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ALMS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ALMS due diligence checks available for Premium users.
Valuation
ALMS fair value
Fair Value of ALMS stock based on Discounted Cash Flow (DCF)
Price
$4.33
Fair Value
$4.90
Undervalued by
11.59%
ALMS ($4.33) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ALMS ($4.33) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ALMS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ALMS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.42x
Industry
-158.75x
Market
29.19x
ALMS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.91x
Industry
4.37x
ALMS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ALMS's financial health
Profit margin
Revenue
$0.0
Net Income
-$94.8M
Profit Margin
0%
ALMS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$341.0M
Liabilities
$80.9M
Debt to equity
0.31
ALMS's short-term assets ($306.19M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ALMS's short-term assets ($306.19M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ALMS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$74.8M
Investing
$31.0M
Financing
$5.0k
ALMS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ALMS vs Biotech Stocks
Alumis Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.